People with Parkinson’s disease who use passive coping strategies, rather than active ones, are more likely to experience worse depression,…
Articles by Marisa Wexler, MS
A multi-faceted intervention that included staff education, electronic alerts, and requiring new reports, improved the timeliness with which Parkinson’s disease patients…
The first participant has been dosed in a Phase 1 clinical trial evaluating the safety of PTC857, PTC Therapeutics‘…
A planned Phase 2 clinical trial evaluating ANVS401, Annovis Bio‘s lead investigational therapy for people in the early stages of …
Many Parkinson’s disease patients in the U.K. feel challenged by the COVID-19 pandemic and the restrictions it has placed on social interaction,…
The U.S. Food and Drug Administration (FDA) has approved the Percept PC Neurostimulator by Medtronic, designed to allow for…
Coenzyme Q10, an antioxidant supplement that, when taken orally, has shown limited effectiveness, can alleviate Parkinson’s disease…
Current Parkinson’s treatments are insufficient for people with late-stage disease, inadequately controlling for many notable motor and non-motor symptoms, a…
Integrative Research Laboratories (IRLAB) is planning a Phase 2b/3 clinical trial of its investigational therapy mesdopetam (IRL790) to…
A $3.7 million federal grant is funding a project aiming to clarify how exposure to manganese, a trace metal, affects…